Table 1 Clinicopathological characteristics of the study cohort
Patient´s characteristics | PABC | non-PABC | p-value (a) | ||
|---|---|---|---|---|---|
All (n = 33) | PABC-GS (n = 15) | PABC-PP (n = 18) | All (n = 26) | ||
Age at diagnosis (years) Median (min–max) | 35.7 (29.6–42.6) | 36.5 (29.5–38.5) | 35.2 (31.6–42.6) | 36.8 (27.0–44.3) | 0.0791 |
Age at menarche (years) Median (min–max) | 12.0 (10.0–15.0) | 12.0 (10.0–14.0) | 12.5 (11.0–15.0) | 12.0 (10.0–14.0) | 0.4879 |
Family history of breast/ovarian cancer (n, %) | |||||
Yes No | 19 (57.6) 14 (42.4) | 7 (46.7) 8 (53.3) | 12 (66.7) 6 (33.3) | 4 (15.4) 22 (84.6) | 0.0012 |
Germline mutations (n, %) | |||||
BRCA1/2 mutation BRCA1/2 WT Unknown | 5 (15.2) 8 (24.2) 20 (60.6) | 1 (6.7) 6 (4.0) 8 (53.3) | 4 (22.2) 2 (11.1) 12 (66.6) | 0 (0) 0 (0) 26 (100) | NA |
Recurrence (n, %) | |||||
Follow-up period (median, years) Yes No | 6.0 10 (30.3) 23 (69.7) | 6.0 3 (20.0) 12 (80.0) | 5.0 7 (38.9) 11 (61.1) | 8.5 7 (26.9) 19 (73.1) | 0.999 |
Recurrence type (n, %) | |||||
Local/regional Distant Unknown NA | 4 (12.1) 5 (15.2) 1 (3.03) 23 (30.3) | 0 (0.0) 3 (20.0) 0 (0.0) 12 (80.0) | 4 (22.2) 2 (11.1) 1 (5.6) 11 (61.1) | 0 (0.0) 3 (11.5) 4 (15.4) 19 (73.1) | 0.115 |
New primary disease (n, %) | |||||
No Yes | 32 (97.0) 1 (3.0) | 15 (100.0) 0 (0.0) | 17 (94.4) 1 (5.6) | 26 (100.0) 0 (0.0) | 0.999 |
No. full-term pregnancy prior to BC (n, %) | |||||
0 1 2 3 | 14 (42.4) 15 (45.5) 3 (9.1) 1 (3.0) | 7 (46.7) 6 (40.0) 2 (13.3) 0 (0.0) | 7 (38.9) 9 (50.0) 1 (5.6) 1 (5.6) | 10 (38.5) 6 (23.0) 10 (38.5) 0 (0.0) | 0.024 |
Child´s gender (n, %) | |||||
Female Male Unknown | 16 (48.5) 15 (45.5) 2 (6.0) | 7 (46.7) 6 (40.0) 2 (13.3) | 9 (50.0) 9 (50.0) 0 (0.0) | NA | NA |
Time of BC diagnosis (n, %) | |||||
Gestation ≤12 months postpartum <5 years after birth ≥5 years after birth Nulliparous | 15 (45.5) 18 (54.5) 0 (0.0) 0 (0.0) 0 (0.0) | 15 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) | 0 (0.0) 18 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) | 0 (0.0) 0 (0.0) 3 (11.5) 13 (50.0) 10 (38.5) | NA |
Pregnancy trimester at BC diagnosis (n, %) | |||||
First (≤12 week) Second (12–27 week) Thrid (>27 week) Unknown | 6 (18.2) 1 (3.0) 3 (9.1) 23 (69.7) | 6 (40.0) 1 (6.7) 3 (20.0) 5 (33.3) | 0 (0.0) 0 (0.0) 0 (0.0) 18 (100.0) | 0 (0.0) 0 (0.0) 0 (0.0) 26 (100.0) | NA |
Tumor´s characteristics | PABC | non-PABC | p-value (a) | ||
|---|---|---|---|---|---|
All (n = 33) | PABC-GS (n = 15) | PABC-PP (n = 18) | All (n = 26) | ||
Histological type (n, %) | |||||
Invasive ductal carcinoma Invasive lobular carcinoma Other types | 29 (87.9) 2 (6.1) 2 (6.1) | 15 (100.0) 0 (0.0) 0 (0.0) | 14 (77.8) 2 (11.1) 2 (11.1) | 22 (84.6) 1 (3.9) 3 (11.5) | 0.7142 |
Clinical subtype (IHC) (n,%) | |||||
Luminal (HR+/HER2−) HER2+ TN (HR−/HER2−) | 12 (36.4) 5 (15.1) 16 (48.5) | 2 (13.3) 6 (40.0) 7 (46.7) | 3 (16.7) 6 (33.3) 9 (50.0) | 10 (38.5) 10 (38.5) 6 (23.0) | 0.0595 |
Tumor size (TNM) (n,%) | |||||
T1–T2 T3–T4unknown | 21 (63.6) 8 (24.2) 4 (12.1) | 9 (60.0) 4 (26.7) 2 (13.3) | 11 (61.1) 4 (22.2) 3 (16.7) | 19 (73.1) 7 (26.9) 0 (0.0) | 0.9560 |
Node invasion (TNM) (n,%) | |||||
N0 N1–3 Unknown | 10 (30.3) 18 (54.5) 5 (15.2) | 10 (66.7) 2 (13.3) 3 (20.0) | 12 (66.7) 4 (22.2) 2 (11.1) | 10 (38.5) 16 (61.5) 0 (0.0) | 0.8345 |
Metastasis (TNM) (n,%) | |||||
M0 M1 Unknown | 30 (90.9) 2 (6.1) 1 (3.0) | 13 (86.7) 1 (6.7) 1 (6.7) | 17 (94.4) 1 (5.6) 0 (0.0) | 24 (92.3) 2 (7.7) 0 (0.0) | 0.8293 |
Histology grade (n,%) | |||||
G1 (low) G2 (intermediate) G3 (high) Unknown | 1 (3.0) 9 (27.3) 18 (54.5) 5 (15.2) | 1 (6.7) 4 (26.7) 9 (60.0) 1 (6.7) | 0 (0.0) 5 (27.8) 9 (50.0) 4 (22.2) | 3 (3.8) 11 (42.3) 11 (42.3) 1 (3.8) | 0.188 |
Tumor-infiltrating lymphocytes (TILs) (n,%) | |||||
<10% ≥10% | 16 (48.5) 17 (51.5) | 9 (60.0) 6 (40.0) | 7 (38.9) 11 (61.1) | NA | NA |
